Allergy Therapeutics Corporate Presentation - January 2016 - Proactive ...

Page created by Terry Lopez
 
CONTINUE READING
Allergy Therapeutics Corporate Presentation - January 2016 - Proactive ...
Allergy Therapeutics

                                                                              Corporate Presentation

                                                                                                     January 2016
Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director
Allergy Therapeutics Corporate Presentation - January 2016 - Proactive ...
Introduction

    We treat people with Allergic disorders

    Focused on the moderate to severe patients

    Providing treatments that cure the disease,
     not just treat symptoms

    Robust revenue growth and successful M&A
     delivered

    c.420 employees

    Spun-out from Smith Kline Beecham 1999

    Headquarters and manufacturing base in
     Worthing, West Sussex

    AIM listed: ticker AGY

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director   2
Allergy Therapeutics Corporate Presentation - January 2016 - Proactive ...
Strategy

    Strong European business
        European market share increased from 8.7% to 10.1%
         over last 2 years

    US opportunity
        Poised to execute a pivotal clinical trial programme to
         enable access to US – estimated $2bn market size

    New therapeutic areas
        Strong new product pipeline expanding the addressable
         markets:

        Peanut allergy- estimated $8bn market size

        House Dust Mite allergy- estimated $3bn market size

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director   3
Allergy Therapeutics Corporate Presentation - January 2016 - Proactive ...
Global presence

                                                                                  Sales and marketing network comprising
                                                                                   c.120 European sales force

                                                                                         UK
                                                                                              Netherlands &        Latvia, Estonia
                                                               Canada
                                                                                                Germany            & Lithuania
                                                                                                                Poland
                                                                                     Austria &                  Czech
                                                                                    Switzerland           Italy Republic &
                                                                                                                Slovakia
                                                                              Portugal
                                                                                                                Greece                    South Korea
                                                                                              Spain

                                                     Venezuela &
                                                      Columbia

                                             Peru

                                                                                                                                     Subsidiaries
                                                Chile
                                                               Argentina                                                             Distributors
                                                                                                                                     New Markets

                   Subsidiaries in 9 countries and distribution agreements in additional 10 countries

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director                           4
Allergy Therapeutics Corporate Presentation - January 2016 - Proactive ...
Sales breakdown

  1.Sales breakdown based on gross sales at budget exchange rates (before freight, discounts, rebates and exchange) : £49.3 million.
  After deducting discounts, rebates, freight charges and foreign exchange adjustments, total sales for FY2015 is £43.2 million

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director                           5
Allergy Therapeutics Corporate Presentation - January 2016 - Proactive ...
The Peanut Allergy Opportunity

         November 2015- exclusive right to develop Virus Like Particles
          (VLP) technology for allergy vaccines

         Carrier system to present allergens to the immune system

         First development will be for peanut allergy

         Currently no established and safe treatment available

         Commencing an R&D investment programme of c.£3m to
          progress the programme through to the start of Phase I trials over
          a 2-3 year period

         Peanut represents a new opportunity into the $8bn worldwide
          food allergy market

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director   6
Allergy Therapeutics Corporate Presentation - January 2016 - Proactive ...
The US opportunity

    Immunotherapy is expected to grow at a CAGR of
     11% to 2020*

    Estimated market: cost to payer $2 billion**

    Currently no registered injected products

    Clinical Development Plan for PQ Grass on track

    Opportunity fully funded

    Estimated launch 2019

    Estimated peak grass sales US$300- US$400
     million
   *Visiongain, AR forecast 2014
   **Piper Jaffray Update on the AR market, Sept. 2008. Datamonitor

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director   7
Allergy Therapeutics Corporate Presentation - January 2016 - Proactive ...
PQ product opportunity

                 Current US SCIT market                                           Allergy Therapeutics’ entry in the US
           • Home made preparation                                                • Standardised dose vaccine

           • Non GMP manufacturing                                                • GMP manufactured
           • Non registered                                                       • FDA submission planned in 2018
           • No clinical evidence                                                 • Multiple clinical studies

           • Long courses of treatment:                                           • Ultra- short course treatment:
              • 50 to 100 injections                                                 • 4 injections

           • Slow to act: 6 to 12 months                                          • Efficacy in 3 weeks

           • Low compliance                                                       • High compliance

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director   8
Allergy Therapeutics Corporate Presentation - January 2016 - Proactive ...
Keys to Success for PQ in the US

           Proprietary Technology
           IP Protected
           De-risked opportunity
                     •      Treated more than 250,000 patients and marketed in 7 countries

           Building on Progress to date in the US:
                     •      US$ 100 million invested in clinical studies to date
                     •      14 clinical trials completed to date, including Phase I, II & III successful studies
                     •      Investigated in over 3,000 patients worldwide, mainly in the US

           Strategic fit for US market*
                     •      Pollinex Quattro is an injected product for an injected market

           First mover advantage
                     •       First to market in the seasonal injected segment
                     •       High entry barriers: regulatory requirements for extensive trials on efficacy and safety

          Source: *The Current States of Therapy for Allergic Rhinitis in the United States. Lawrence Du Buske, MD.

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director          9
Competitive Landscape

    Four listed companies compete to lead the market in Europe and the US

               •      ALK
                    •      Grastek: SLIT-Pill for grass allergy. Launched in the US
                    •      Ragwitek: SLIT-Pill for ragweed allergy. Launched in the US
               •      Stallergenes
                    •      Oralair: SLIT-Pill for grass allergy. Launched in the US

               •      Allergy Therapeutics
                    •      Pollinex Quattro: ultra-short SCIT for grass allergy. US launch expected in 2019
               •      Circassia
                    •      ToleroMune: ultra-short SCIT for cat allergy. In clinical development

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director   10
2016 Expected News flow

                      Q1 2016                             US- PQ Grass 204- recruitment update
                      8 March                             Interims
                      Q2 2016                             Europe- PQ Birch 204- headline results
                      Q2 2016                             US- PQ Grass 204- headline results
                      Q4 2016                             US- Initiate G306 study recruitment
                      Q4 2016                             Europe- Clinical Trial Approval for PQ Birch 301

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director    11
Summary

            Immunotherapy is expected to be the fastest growing segment in the allergic rhinitis
             treatment market

            Raised £20m March 2015 (21p) to fund US opportunity for Pollinex Quattro Grass
               Planned launch in 2019

            Raised £11m November 2015 (28p) to
                       Accelerate core business growth
                       Open peanut allergy opportunity

      • Strong trading in the first half of the financial year: +12% growth at constant currency

                                      We are delivering on all aspects of our growth strategy

Proactive Investors 28th January 2016 – Ian Postlethwaite, Finance Director   12
You can also read